NASDAQ:CAPR

Capricor Therapeutics Stock Forecast, Price & News

$4.27

+0.01 (+0.23 %)

(As of 08/5/2021 12:00 AM ET)

Add

Compare

Today's Range

$4.15

▼

$4.40

50-Day Range

$3.79

▼

$5.72

52-Week Range

$3.13

▼

$8.40

Volume130,130 shs

Average Volume659,425 shs

Market Capitalization$97.69 million

P/E RatioN/A

Dividend YieldN/A

Beta6.5

30 days | 90 days | 365 days | Advanced Chart

Receive CAPR News and Ratings via Email

Sign-up to receive the latest news and ratings for Capricor Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

About Capricor Therapeutics

Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.

Capricor Therapeutics to Present Second Quarter 2021 Financial Results and Recent Corporate Update on August 12
August 5, 2021 | finance.yahoo.com

Capricor Therapeutics Announces the Appointment of Karimah Es Sabar to its Board of Directors
July 27, 2021 | finance.yahoo.com

Capricor Therapeutics, Inc. Common Stock (CAPR)
July 17, 2021 | nasdaq.com

Strength Seen in Capricor (CAPR): Can Its 5.7% Jump Turn into More Strength?
June 23, 2021 | finance.yahoo.com

Capricor Therapeutics to Present Findings from HOPE-2 Open-Label Extension Study at Parent Project Muscular Dystrophy (PPMD) 2021 Virtual Annual Conference
June 17, 2021 | finance.yahoo.com

Hedge Funds Are Betting On Capricor Therapeutics, Inc. (CAPR)
June 13, 2021 | finance.yahoo.com

Capricor Therapeutics to Participate in BIO Digital 2021 Conference
June 10, 2021 | finance.yahoo.com

Global Exosomes Pipeline Insight Report 2021: Insights on Approx 50+ Companies and 70+ Pipeline Drugs - ResearchAndMarkets.com
June 8, 2021 | ca.finance.yahoo.com

Capricor To Present Preclinical Data for Exosome-mRNA Vaccine for SARS-CoV-2 at the International Society for Extracellular Vesicles (ISEV) Annual Meeting
May 18, 2021 | finance.yahoo.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CAPR
Previous Symbol
CUSIPN/A
CIK1133869
Webwww.capricor.com
Phone310-358-3200
EmployeesN/A
Year FoundedN/A

Sales & Book Value

Annual Sales$310,000.00
Price / Sales315.13
Cash FlowN/A
Price / Cash FlowN/A
Book Value$1.38 per share
Price / Book3.09

Profitability

EPS (Most Recent Fiscal Year)($0.88)
Net Income$-13,660,000.00
Net Margins-10,074.70%
Return on Equity-52.82%
Return on Assets-44.16%

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares22,878,000
Market Cap$97.69 million
Next Earnings Date8/5/2021 (Estimated)
OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

1.55 out of 5 stars

Medical Sector

979th out of 1,311 stocks

Pharmaceutical Preparations Industry

485th out of 647 stocks

3.5 Analyst's Opinion

Consensus Rating
Capricor Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $12.00, Capricor Therapeutics has a forecasted upside of 181.0% from its current price of $4.27.
Amount of Analyst Coverage
Capricor Therapeutics has received no research coverage in the past 90 days.

4.3 Community Rank

Outperform Votes
Capricor Therapeutics has received 328 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Capricor Therapeutics has received 186 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Capricor Therapeutics has received 63.81% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Capricor Therapeutics and other stocks. Vote “Outperform” if you believe CAPR will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CAPR will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Capricor Therapeutics does not currently pay a dividend.
Dividend Growth
Capricor Therapeutics does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Capricor Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 8.60% of the stock of Capricor Therapeutics is held by insiders.
Percentage Held by Institutions
Only 19.03% of the stock of Capricor Therapeutics is held by institutions.

0.0 Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Capricor Therapeutics is -4.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Capricor Therapeutics is -4.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Capricor Therapeutics has a P/B Ratio of 3.09. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Capricor Therapeutics (NASDAQ:CAPR) Frequently Asked Questions

Is Capricor Therapeutics a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Capricor Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Capricor Therapeutics stock.
View analyst ratings for Capricor Therapeutics or view top-rated stocks.

What stocks does MarketBeat like better than Capricor Therapeutics?

Wall Street analysts have given Capricor Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Capricor Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Capricor Therapeutics' next earnings date?

Capricor Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Capricor Therapeutics.

How were Capricor Therapeutics' earnings last quarter?

Capricor Therapeutics Inc (NASDAQ:CAPR) announced its quarterly earnings results on Thursday, May, 13th. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter. The biotechnology company earned $0.04 million during the quarter. Capricor Therapeutics had a negative net margin of 10,074.70% and a negative trailing twelve-month return on equity of 52.82%.
View Capricor Therapeutics' earnings history.

How has Capricor Therapeutics' stock been impacted by Coronavirus (COVID-19)?

Capricor Therapeutics' stock was trading at $1.0050 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CAPR shares have increased by 324.9% and is now trading at $4.27.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for CAPR?

1 equities research analysts have issued 12-month price targets for Capricor Therapeutics' shares. Their forecasts range from $12.00 to $12.00. On average, they expect Capricor Therapeutics' stock price to reach $12.00 in the next year. This suggests a possible upside of 181.0% from the stock's current price.
View analysts' price targets for Capricor Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Capricor Therapeutics' key executives?

Capricor Therapeutics' management team includes the following people:

Frank I. Litvack M.D., Independent Executive Chairman of the Board (Age 59)
Linda Marban Ph.D., President, Chief Executive Officer, Director (Age 51)
Anthony Bergmann, Chief Financial Officer, Principal Accounting Officer (Age 32)
Karen G. Krasney J.D., Executive Vice President, General Counsel (Age 62)
Thomas Lyle Copmann Ph.D., Vice President - Regulatory Affairs and Drug Development (Age 61)
Houman Hemmati M.D., Ph.D., Vice President - Medical & Clinical Development, New Therapies
Luis Rodriguez-Borlado Ph.D., Vice President - Regenerative Therapies
Rachel Smith Ph.D., Vice President - Research & Development (Age 36)
Deborah Ascheim M.D., Chief Medical Officer
Joshua A. Kazam, Director (Age 40)

Who are some of Capricor Therapeutics' key competitors?

Some companies that are related to Capricor Therapeutics include Homology Medicines (FIXX), Forte Biosciences (FBRX), CytomX Therapeutics (CTMX), Magenta Therapeutics (MGTA), Inozyme Pharma (INZY), TherapeuticsMD (TXMD), Biomea Fusion (BMEA), BioDelivery Sciences International (BDSI), Verona Pharma (VRNA), Vera Therapeutics (VERA), Alzamend Neuro (ALZN), 89bio (ETNB), Athersys (ATHX), Amryt Pharma (AMYT) and Annovis Bio (ANVS).
View all of CAPR's competitors.

What other stocks do shareholders of Capricor Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Capricor Therapeutics investors own include Marinus Pharmaceuticals (MRNS), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Vaxart (VXRT), Inovio Pharmaceuticals (INO), Trevena (TRVN), Dynavax Technologies (DVAX), Chesapeake Energy (CHKAQ), OPKO Health (OPK) and Advanced Micro Devices (AMD).

What is Capricor Therapeutics' stock symbol?

Capricor Therapeutics trades on the NASDAQ under the ticker symbol "CAPR."

Who are Capricor Therapeutics' major shareholders?

Capricor Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include GSA Capital Partners LLP (0.49%) and Cutler Group LP (0.00%).
View institutional ownership trends for Capricor Therapeutics.

Which major investors are buying Capricor Therapeutics stock?

CAPR stock was acquired by a variety of institutional investors in the last quarter, including GSA Capital Partners LLP, and Cutler Group LP.
View insider buying and selling activity for Capricor Therapeutics or or view top insider-buying stocks.

How do I buy shares of Capricor Therapeutics?

Shares of CAPR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Capricor Therapeutics' stock price today?

One share of CAPR stock can currently be purchased for approximately $4.27.

How much money does Capricor Therapeutics make?

Capricor Therapeutics has a market capitalization of $97.69 million and generates $310,000.00 in revenue each year. The biotechnology company earns $-13,660,000.00 in net income (profit) each year or ($0.88) on an earnings per share basis.

What is Capricor Therapeutics' official website?

The official website for Capricor Therapeutics is www.capricor.com.

Where are Capricor Therapeutics' headquarters?

Capricor Therapeutics is headquartered at 8840 WILSHIRE BLVD 2ND FLOOR, BEVERLY HILLS CA, 90211.

How can I contact Capricor Therapeutics?

Capricor Therapeutics' mailing address is 8840 WILSHIRE BLVD 2ND FLOOR, BEVERLY HILLS CA, 90211. The biotechnology company can be reached via phone at 310-358-3200 or via email at [email protected]

This page was last updated on 8/5/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here